Report And Consolidated Financial Statements

Overview

The report describes continued progress in the P140 autoimmune platform, including new mechanism-of-action evidence and revised SLE/CIDP study planning. It reports no group revenue for 2024 and a consolidated loss of £2,483,499. Governance disclosures state that the Board adopted the QCA Code and continued oversight of risks, stakeholders and environmental considerations.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2024
Period: Ends 31 December 2024
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services